Phio Pharmaceuticals Corp. 8-K

What Happened Phio Pharmaceuticals Corp. (PHIO) filed a Form 8-K on January 20, 2026 to announce tumor response data from all cohorts in its intratumoral PH-762 dose-escalation trial in cutaneous carcinoma. The company reported favorable safety and tolerability across all dose escalations and released the full results in a press release (filed as Exhibit 99.1).

Key Details

• Reported date: January 20, 2026 (8-K filing and press release).
• Safety: Favorable safety and tolerability observed at all dose escalation levels.
• Efficacy: Pathology data showed a 70% overall response rate (ORR) for squamous cell carcinomas.
• Complete responses: Of the 14 responders reported, 10 patients (10 of 14) had 100% clearance.

Why It Matters This 8-K provides a clinical update showing positive safety and efficacy signals for PH-762 in cutaneous squamous cell carcinoma, a key early-stage readout for the program. For investors, the data could be an important de-risking milestone for PH-762’s development pathway and may inform the company’s next clinical or regulatory steps; the press release is attached to the filing for full details.